hNeo-T

Phase 1Biologic

BBGI, China

hNeo-T is one of 31 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Recruiting·BBGI, China·Phase 1·NCT06224049·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hNeo-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hNeo-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hNeo-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BGI, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBGI, China

hNeo-T

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News